Financial Performance & Outlook - Revenue for Q1 2025 was $40.8 million[10] - The company is targeting revenue in the range of $165 million to $175 million for 2025[10] - Non-GAAP operating expenses decreased by 22% year-over-year in Q1 2025[10, 17, 53] - Adjusted EBITDA improved by 29% year-over-year in Q1 2025[10, 17, 58] - Non-GAAP Gross Margin was 53% in Q1 2025[49] Cash Position & Cost Reduction - The company had $261 million in cash, cash equivalents, restricted cash, and short-term investments as of March 31, 2025[10, 22, 62] - The company operationalized approximately $10 million in cost reductions in Q1 2025, totaling $90 million since the merger[10] Strategic Initiatives - The company is rolling out new proteomics solutions and Illumina NGS[10] - The company is targeting adjusted EBITDA positive in 2026[10, 19, 64] SomaLogic Merger - The company is targeting $80 million in synergies from the SomaLogic merger[19, 22]

Recent Highlights: "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and disciplined, driving a 29% year-over-year improvement in adjusted EBITDA through Standard BioTools Business System (SBS). We believe our unique model, world class operational platform and healthy capital position will allow ...

Core Insights - Standard BioTools reported a solid first quarter in 2025, achieving a 29% year-over-year improvement in adjusted EBITDA despite a challenging macro environment in Life Sciences [2][5] - The company is focused on its strategic position in proteomics, particularly with the SomaScan and SOMAmers technologies, which are gaining traction in population-based studies [2][5] Financial Performance - Revenue for the first quarter of 2025 was $40.8 million, a decrease of 10% compared to $45.5 million in the first quarter of 2024 [3][6] - Consumables revenue was $14.5 million, down 16% year-over-year, while instruments revenue increased by 24% to $7.8 million, driven by growth in the Hyperion XTi spatial proteomics platform [6][22] - Services revenue totaled $17.6 million, down 16% year-over-year, with Lab Services revenue declining by 19% due to tough comparisons with prior-year levels [6][22] Profitability Metrics - Gross margin for the first quarter of 2025 was 48.4%, down from 53.1% in the same period of 2024, while non-GAAP gross margin was 53.2%, down from 56.2% [3][7] - Operating expenses decreased significantly to $52.7 million, down 38% from $84.4 million in the first quarter of 2024, reflecting cost synergies from the merger [12][24] - The net loss for the first quarter was $26.0 million, an improvement from a net loss of $32.2 million in the first quarter of 2024 [12][26] Cash Position - As of March 31, 2025, the company had a strong balance sheet with $261 million in cash and cash equivalents and no material debt [5][17] - The company operationalized an additional $10 million in annual run rate cost reductions, totaling $90 million since the merger [5][12] Future Outlook - For the fiscal year 2025, Standard BioTools expects revenue in the range of $165 million to $175 million, anticipating a decline in Americas academic revenue due to NIH funding pressures [8][12]

Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next- generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Associat ...

Core Viewpoint - Standard BioTools Inc. is set to report its first quarter 2025 financial results on May 6, 2025, after market close, followed by a conference call to discuss these results and operational progress [1]. Company Overview - Standard BioTools Inc. (Nasdaq: LAB) offers a portfolio of next-generation technologies aimed at accelerating biomedical research and improving medicine development [3]. - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights into health and disease, facilitating better patient outcomes [3]. - Standard BioTools collaborates with various sectors including academic, government, pharmaceutical, and biotechnology research, focusing on critical areas in translational and clinical research like oncology and immunology [3].

Strong Financial Position with Approximately $18.1 Million Cash to Support Strategic Growth InitiativesTORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to provide an update on the Company’s strategic progress, including its ongoing efforts to secure a significant gold project, as well as recent developments concerning its New Found Gold holdings. Project Acquisition Update As part of its growth strategy, Labrador G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charte ...

Standard BioTools Inc. (NASDAQ:LAB) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. It's now my pleasure to intro ...

Non-GAAP financial information Setting Standards Empowering Research Building Shareholder Value Q4 and 2024 Full Year Financial Results February 26th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing ...

Financial Performance - Standard BioTools reported a revenue of $174 million from two acquisitions, with a path to profitability by 2026[43]. - Q3 2024 total revenue was $45 million, a decrease of 5% year-over-year, with consumables revenue growing by 13% to $14 million[68]. - The company reported a net loss of $27 million for Q3 2024, an improvement of $14 million compared to the previous year[76]. - Instrument revenue declined by 42% year-over-year to $6 million, attributed to continued capital spending constraints[70]. - Collaboration and other revenue increased by 10% year-over-year to $1 million[68]. Operational Efficiency - The company achieved a 32% improvement in adjusted EBITDA year-to-date Q3 2024, with a 98% on-time delivery rate in Q4 2024 compared to 78% in Q4 2022[27]. - Non-GAAP operating expenses were reduced by 17% year-over-year from 2022 to 2023, contributing to a 53% decrease in cash use[33]. - Operating expenses for Q3 2024 were reduced by 24% year-over-year to $40 million, representing 89% of revenue[74]. - Standard BioTools has reduced customer complaints by fourfold and improved delivery reliability through lean transformation initiatives[43]. - The company is focused on increasing ROI and diversifying risk while maintaining operational efficiency[64]. Market Strategy - Standard BioTools is focusing on expanding its service offerings to increase technology adoption in the biopharma market, which is estimated at $13 billion[13]. - The company aims to transition to an 80% consumable and services mix, enhancing its revenue stability[43]. - The product mix is shifting towards higher-margin consumables, targeting an increase from 53% to 65% gross margin by Q3[13]. - The proteomics market is projected to grow at a CAGR of 14.9%, with a total addressable market of $110 billion by 2032[50]. Mergers and Acquisitions - The merger with SomaLogic is expected to generate $250 million in EBITDA synergies by FY 2026[35]. - The company has a net cash position of $311 million as of Q3 2024, enabling future M&A activities[39]. Research and Development Expenses - GAAP R&D expenses for Q3 YTD 2024 were $48.4 million, compared to $19.0 million in Q3 YTD 2023, reflecting a significant increase[88]. - Non-GAAP R&D expenses for Q3 YTD 2024 were $41.3 million, up from $17.4 million in Q3 YTD 2023, indicating a growth of approximately 137%[88]. - Stock-based compensation in R&D for Q3 YTD 2024 was $4.5 million, consistent with the previous year[88]. - Depreciation and amortization in R&D for Q3 YTD 2024 was $2.6 million, consistent with the previous year[88]. Selling, General and Administrative Expenses - GAAP SG&A expenses for Q3 YTD 2024 reached $119.0 million, compared to $66.2 million in Q3 YTD 2023, representing an increase of about 80%[88]. - Non-GAAP SG&A expenses for Q3 YTD 2024 were $95.9 million, up from $56.9 million in Q3 YTD 2023, showing an increase of approximately 68%[88]. - Stock-based compensation in SG&A for Q3 YTD 2024 was $18.9 million, compared to $7.8 million in Q3 YTD 2023, reflecting a growth of about 142%[88]. - Depreciation and amortization in SG&A for Q3 YTD 2024 was $3.3 million, unchanged from the previous year[88]. - Loss on disposal of PP&E in SG&A for Q3 YTD 2024 was $0.4 million, compared to $0.1 million in Q3 YTD 2023[88]. Cash Position - Cash and equivalents at September 30, 2024, totaled $368 million, supporting ongoing growth initiatives[83]. - Market capitalization as of September 30, 2024, was $718 million, with an enterprise value of $350 million[83].